K-pop

143 Entertainment, Icon’s Agency, Appoints Koji Masai as First Chairman

Korean-Japanese Businessman Running an IP Investment Firm "Pushing to Expand Artist IP Through New Artist Launches and More"

KIM HYUNSIK
2026-07-20 11:51:06
[Edaily Starin KIM HYUNSIK Reporter] 143 Entertainment announced on the 20th that it has appointed Koji Masai, a Korean-Japanese businessman, as its first chairman.
From left: Maydin, Chairman Koji Masai, iKON (Photo courtesy of 143 Entertainment)
143 Entertainment is the agency representing the boy group iKON and the girl group Maydin. Creative Farm, led by Chairman Koji Masai, operates Masai Holdings, an entertainment intellectual property (IP) investment company.
143 Entertainment explained, “Chairman Koji Masai has developed various businesses based on real estate investments, and while continuously investing in the entertainment industry, he has shown interest in expanding Korean artists’ activities in Japan and cultural projects.”
143 Entertainment also announced that it has signed a strategic investment agreement with Creative Farm. Based on this agreement, the company plans to expand its artist IP portfolio, including the launch of new groups.
143 Entertainment added, “We plan to sequentially launch new boy groups and girl groups in the future and strive to expand our portfolio by recruiting competitive, high-profile artists.”
Chairman Koji Masai stated, “I highly value 143 Entertainment’s content competitiveness and growth potential,” adding, “I will do my part to ensure the company’s sustained growth through responsible investment and stable support.”

Economy

Corporation

IT·Science

Economy

SK Hanik Surprised by Rumors of a '16 Trillion Won' Special Dividend… "Additional Shareholder Returns to Be Announced on the 28th"

SK hynix announced that it is reviewing various shareholder return measures, including the possibility of a special dividend using the capital gains from its investment in Japanese semiconductor compa…
2026-10-26 10:32:59

Corporation

[ESMO 2026] Ok Chan-young, Director of the Ligacem Center: “LCB02A Expected to Be Effective Even in Patients with Low Claudin 18.2 Expression”

“LCB02A uses exatecan as its payload. Drugs in the exatecan class have a bystander effect that allows them to attack surrounding cancer cells, and this effect is expected to be further enhanced throug…
2026-10-26 11:22:02

IT·Science

DongKook Life Science Co., Ltd. Plans to Change Company Name to ‘DK Ruonics’… to Expand New Drug and CMO Businesses

#DongKook Life Science Co., Ltd. is moving forward with a plan to change its company name to “DK Luonix.” Through this change, the company plans to expand its business scope from its current focus on …
2026-10-26 13:42:02